SPROSpero Therapeutics, Inc.
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The…
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
Older | ||
 Spero Therapeutics (SPRO) Q2 2026 Earnings Call Transcript CEO Rajavelu discusses $105 million financing and SP001 immunology strategy. | ||
Spero Therapeutics, Inc. Q2 2026 Earnings Call Summary Moby summary of Spero Therapeutics, Inc.'s Q2 2026 earnings call | ||
Spero Therapeutics Inc (SPRO) (Q2 2026) Earnings Call Highlights: FDA Approval of Utebzi and ... SPRO strengthens its balance sheet and extends cash runway into 2029 while advancing its new SP001 immunology pipeline following the landmark approval of the first oral carbapenem antibiotic. | ||
 Spero Therapeutics Q2 Earnings Call Highlights Spero Therapeutics (NASDAQ:SPRO) used its second-quarter update to outline a strategic shift toward immune-mediated diseases, supported by the FDA approval of Utebzi and a new licensing agreement for SP001, an antibody candidate the company plans to develop initially for IgG4-related disease. Presi | ||
 Innovent licenses IBI355 rights to Spero for up to $1.1bn Spero will hold rights to the antibody in all markets except Mainland China, Hong Kong, Macau, and Taiwan. | ||
 J&J dips despite upbeat outlook; AstraZeneca, Spero cut China deals J&J’s shares ticked down as oncology sales missed expectations. Elsewhere, AstraZeneca bet $600 million on a lung cancer drug and a pair of biotechs snagged two of the year’s top venture rounds. | ||
 Spero Therapeutics Lands $105 Million Royalty Financing to Advance SP001 Development (SPRO) Spero Therapeutics, Inc. (NASDAQ:SPRO) has entered into a $105 million non-recourse, non-dilutive royalty financing agreement with affiliates of HealthCare Royalty (HCRx), a company majority owned by KKR & Co. | ||
IInsider Monkey | ||